| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642911 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(4 years from now) | |
| US8889109 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(4 years from now) | |
Valcyte is owned by Hoffmann La Roche.
Valcyte contains Valganciclovir Hydrochloride.
Valcyte has a total of 2 drug patents out of which 0 drug patents have expired.
Valcyte was authorised for market use on 28 August, 2009.
Valcyte is available in for solution;oral dosage forms.
The generics of Valcyte are possible to be released after 11 December, 2027.
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2009
Treatment: NA
Dosage: FOR SOLUTION;ORAL
How can I launch a generic of VALCYTE before it's drug patent expiration?
More Information on Dosage
VALCYTE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic